GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Landos Biopharma Inc (NAS:LABP) » Definitions » EV-to-EBITDA

Landos Biopharma (Landos Biopharma) EV-to-EBITDA : 0.18 (As of May. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Landos Biopharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Landos Biopharma's enterprise value is $-4.12 Mil. Landos Biopharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-22.73 Mil. Therefore, Landos Biopharma's EV-to-EBITDA for today is 0.18.

The historical rank and industry rank for Landos Biopharma's EV-to-EBITDA or its related term are showing as below:

LABP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.73   Med: 1.1   Max: 1.48
Current: 0.18

During the past 6 years, the highest EV-to-EBITDA of Landos Biopharma was 1.48. The lowest was -16.73. And the median was 1.10.

LABP's EV-to-EBITDA is ranked better than
89.39% of 462 companies
in the Biotechnology industry
Industry Median: 9.49 vs LABP: 0.18

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Landos Biopharma's stock price is $22.33. Landos Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.460. Therefore, Landos Biopharma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Landos Biopharma EV-to-EBITDA Historical Data

The historical data trend for Landos Biopharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Landos Biopharma EV-to-EBITDA Chart

Landos Biopharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - - -2.65 0.61 1.15

Landos Biopharma Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.61 1.28 1.25 1.34 1.15

Competitive Comparison of Landos Biopharma's EV-to-EBITDA

For the Biotechnology subindustry, Landos Biopharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Landos Biopharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Landos Biopharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Landos Biopharma's EV-to-EBITDA falls into.



Landos Biopharma EV-to-EBITDA Calculation

Landos Biopharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-4.117/-22.727
=0.18

Landos Biopharma's current Enterprise Value is $-4.12 Mil.
Landos Biopharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Landos Biopharma  (NAS:LABP) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Landos Biopharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=22.33/-3.460
=At Loss

Landos Biopharma's share price for today is $22.33.
Landos Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.460.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Landos Biopharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Landos Biopharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Landos Biopharma (Landos Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 11239, Blacksburg, VA, USA, 24060
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages.
Executives
Alka Batycky director C/O LANDOS BIOPHARMA, INC., P.O. BOX 11239, BLACKSBURG VA 24062
Perceptive Xontogeny Venture Fund Ii, Lp 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Roderick Wong 10 percent owner C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fabio Cataldi officer: Chief Medical Officer C/O LANDOS BIOPHARMA, INC., PO BOX 11239, BLACKSBURG VA 24062
Gregory Oakes director, officer: Chief Executive Officer 760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
Patrick Truesdell officer: Vice President and Controller C/O LANDOS BIOPHARMA, INC., 1800 KRAFT DRIVE, SUITE 216, BLACKBURG VA 24060
Roger Adsett director 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Josep Bassaganya-riera director, 10 percent owner, officer: Chairman, President and CEO 1800 KRAFT DRIVE, SUITE 100, BLACKSBURG VA 24060
Patricia L Bitar officer: Interim CFO C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122
Perceptive Xontogeny Venture Fund, Lp director C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Xontogeny, Llc director 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Fred Callori director 100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Joseph Edelman director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003